



New Biomarkers for Diagnosis and Therapy in Civilization Diseases

Guest Editors:

Dr. Umberto Basile

Head of Clinical Pathology Unit,
Hospital “Santa Maria Goretti”
ASL Latina, Latina, Italy

Prof. Dr. Silvia Angeletti

1. Operative Research Unit of
Laboratory, Fondazione
Policlinico Universitario Campus
Bio-Medico, Via Alvaro del
Portillo, 200, 00128 Rome, Italy
2. Research Unit of Clinical
Laboratory Science, Department
of Medicine and Surgery,
Università Campus Bio-Medico di
Roma, Via Alvaro del Portillo, 21,
00128 Rome, Italy

Deadline for manuscript
submissions:


closed (10 November 2023)

Message from the Guest Editors

The cell surface markers has become an indispensable tool for diagnosing hematological malignancies and monitoring minimal residual diseases. The increase of average age highlights neurodegenerative pathologies and the presence of inflammation, representing new challenges in therapies and biomarker research fields. The applications of gene chips and microarray technology to simultaneously assess multiple molecular markers with Next-Generation Sequencing (NGS), used to sequence entire genomes or constrained to specific areas of interest, are simple and cheaper. Bioluminex, Planar Array Assay and other new assays open new scenarios for autoimmune diseases. The use of different matrixes, such as saliva, cerebrospinal fluid, tears and synovial fluids, will be evaluated.

The aim of this Special Issue is to invite original research articles or reviews presenting and discussing the advancement of biomarkers research and innovative therapies involved in cancer, autoimmune diseases and neurodegenerative diseases, with a special interest in the use of biological drugs in these pathologies and advances in genetics, in innovative assays and in molecular diagnostics.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory
Medicine and Pathobiology,
Department of Surgery,
University of Toronto, 6 Queens
Pk Crescent W,F, Toronto, ON
M5S 3H2, Canada

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [PubMed](#), [PMC](#), [Embase](#), and [other databases](#).

Journal Rank: CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)